Vitrafy Life Sciences Ltd. · ASX:VFY
Vitrafy Life Sciences — Q2 FY2026 Earnings Presentation
8 slides from Vitrafy Life Sciences's earnings presentation, Jan 29, 2026
Slide 1: Q2 FY26 Activities Report
For personal use only Vitrafy Life Sciences Limited Q2 FY26 Activities Report 29 January 2026 Vitrafy Life Sciences Limited (ASX: VFY) ACN 622 720 254 vitrafy.com 1
Slide 2: Overview
Overview For personal use only Strategic Commercial Guardion Arrives in Board Agreement the U.S. Renewal With global, animal First Guardion device Biotech veterans join the board Vitrafy made reproduction leader, (previously known as - Dr Leigh Farrell, Chair, and Dr meaningful IMV Technologies VCU2
Slide 3: Animal Health Commercialisation Highlights
Animal Health Commercialisation Highlights For personal use only Exclusive 12-month strategic commercial agreement with First major global animal insemination market leader IMV commercial milestone Technologies. Animal reproductive biological material market-ready Co-development cryopreservation sol
Slide 4: Product and Commercialisation Highlights
Product and Commercialisation Highlights For personal use only First Guardion device First (beta) Guardion device built and arrived in the U.S. to arrives in the U.S. support sales and marketing activities Four commercial-grade Guardion units built, additional Commercial device builds underway with
Slide 5: General Highlights
General Highlights U.S. footprint secured For personal use only • U.S. base of operations secured in Irvine, California. • Co-located with design and manufacturing partner, Planet Innovation. • Office space and demonstration area to facilitate customer demonstrations, feedback and training – support
Slide 6: Financial Highlights
Financial Highlights Cash Costs per Quarter $6,000 A$m use only Cash costs proceed in line with $5,000 expectation: • Net cash burn $3.0m for the $4,000 quarter. • Cash costs ~$5.0m for the For personal $3,000 quarter compared to ~$4.2m for prior quarter $2,000 Income of ~$2.0m received associated $
Slide 7: Financial Update: Liquidity Overview
Financial Update Liquidity Overview For personal use only $25.00 • Cash and short-term assets at the end of the quarter were A$22.8m. $20.00 $10.10 • Industry Growth Program grant funding A$m $15.00 balance of ~A$1.6m due over the next 12 months. $10.00 • Based on current outlook, Vitrafy has cash $
Slide 8: Outlook
Outlook Vitrafy remains focussed on executing commercialisation in our target market of North America and with our partner in the animal reproduction application, IMV Technologies. For personal use only • The next 6 months for the Company will be focussed on: • Converting existing customer pipeline
Vitrafy Life Sciences — Q2 FY2026 Earnings Presentation on 6ix